Article

Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.

Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
The Lancet (Impact Factor: 45.22). 11/2009; 374(9703):1754-64. DOI: 10.1016/S0140-6736(09)61492-6
Source: PubMed

ABSTRACT Some studies suggest that patients with asthma who are homozygous for arginine at the 16th amino acid position of the beta2-adrenergic receptor (B16 Arg/Arg) benefit less from treatment with longacting beta2 agonists and inhaled corticosteroids than do those homozygous for glycine (B16 Gly/Gly). We investigated whether there is a genotype-specific response to treatment with a longacting beta2 agonist in combination with inhaled corticosteroid.
In this multicentre, randomised, double-blind, placebo-controlled trial, adult patients with moderate asthma were enrolled in pairs matched for forced expiratory volume in 1 s and ethnic origin, according to whether they had the B16 Arg/Arg (n=42) or B16 Gly/Gly (n=45) genotype. Individuals in a matched pair were randomly assigned by computer-generated randomisation sequence to receive inhaled longacting beta2 agonist (salmeterol 50 microg twice a day) or placebo given in a double-blind, crossover design for two 18-week periods. Open-label inhaled corticosteroid (hydrofluoroalkane beclometasone 240 microg twice a day) was given to all participants during the treatment periods. The primary endpoint was morning peak expiratory flow (PEF). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00200967.
After 18 weeks of treatment, mean morning PEF in Arg/Arg participants was 21.4 L/min (95% CI 11.8-31.1) higher when participants were assigned to receive salmeterol than when assigned to receive placebo (p<0.0001). In Gly/Gly participants, morning PEF was 21.5 L/min (11.0-32.1) higher when participants were assigned to receive salmeterol than when assigned to receive placebo (p<0.0001). The improvement in PEF did not differ between genotypes (difference [Arg/Arg-Gly/Gly] -0.1, -14.4 to 14.2; p=0.99). In Gly/Gly participants, methacholine PC20 (20% reduction in forced expiratory volume in 1 s; a prespecified secondary outcome) was 2.4 times higher when participants were assigned to salmeterol than when assigned to placebo (p<0.0001). Responsiveness to methacholine did not differ between salmeterol and placebo in Arg/Arg participants (p=0.87). The 2.5 times higher genotype-specific difference in responsiveness to methacholine was significant (1.32 doubling dose difference between genotypes, 0.43-2.21, p=0.0038). Seven Arg/Arg participants (placebo, n=5; salmeterol, n=2) and six Gly/Gly participants (placebo, n=3; salmeterol, n=3) had an asthma exacerbation. Five serious adverse events were reported, one each during the pre-match and run-in phases on open-label inhaled corticosteroid, two during double-blind treatment with salmeterol/inhaled corticosteroid, and one during double-blind treatment with placebo/inhaled corticosteroid. None of the serious events was asthma-related or related to study drugs or procedures.
In asthma patients with B16 Arg/Arg and B16 Gly/Gly genotypes, combination treatment with salmeterol and inhaled corticosteroid improved airway function when compared with inhaled corticosteroid therapy alone. These findings suggest that patients should continue to be treated with longacting beta2 agonists plus moderate-dose inhaled corticosteroids irrespective of B16 genotype. Further investigation is needed to establish the importance of the genotype-specific difference in responsiveness to methacholine.
National Institutes of Health.

Download full-text

Full-text

Available from: Michael E Wechsler, Jul 08, 2015
0 Followers
 · 
150 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A theoretical investigation has been made of an optically biased, two terminal InP/In<sub>0.33</sub>Ga<sub>0.47</sub>As photo-heterojunction bipolar transistor, using drift diffusion and Monte Carlo models. Comparisons have been made using both models with experimental data for two device structures. Good agreement has been found between the drift diffusion model and experiment for the optical gain, but poorer agreement with the cutoff frequency and current-voltage characteristics. Results from the Monte Carlo model show that discrepancies between the drift-diffusion results and experimental current-voltage characteristics are likely to be due to hot electron effects within the devices
    High Performance Electron Devices for Microwave and Optoelectronic Applications, 1997. EDMO. 1997 Workshop on; 12/1997
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thermal test chips are widely used to develop electronic packaging thermal solutions and to evaluate electronic package assembly processes. Temperature sensors are an integral component on thermal test chips. Unfortunately, each temperature sensor must be calibrated in order for them to be effective. Each calibration can take up to one hour to complete. In a time when increasing sample sizes and shorter development cycles are taxing current equipment and manpower resources, new calibration techniques must be established to keep development costs down. This paper discusses simplified calibration procedures, which can significantly reduce the time needed for temperature sensor calibration. The simplified calibration procedures utilize single-resistance measurements either at room temperature or at the anticipated test temperature. For four different test chip designs included in this study, calibration error variations of less than ±0.6°C at a ±2σ confidence level are possible. The simplified calibration procedures can be applied to any resistor type temperature sensor which has a linear correlation between its electric resistive properties and temperature
    Thermal and Thermomechanical Phenomena in Electronic Systems, 1998. ITHERM '98. The Sixth Intersociety Conference on; 06/1998
  • [Show abstract] [Hide abstract]
    ABSTRACT: Asthma is a common disease characterized by airway inflammation and bronchorestriction. There are several common categories of medications for treating asthma; however, not all asthmatics have the same response to these medications, some of which are adverse responses that are potentially life threatening. Because interindividual responses to asthma medications can vary considerably, the potential for genetic contributions to variable drug responses is significant. This chapter reviews the most common biological pathways targeted by asthma therapy and briefly discusses the genetic contribution to varied responses to asthma therapy for four common types of asthma medications: beta-agonists, anticholinergics, leukotriene modifiers, and corticosteroids.
    Methods in Molecular Biology 02/2008; 448:359-78. DOI:10.1007/978-1-59745-205-2_11 · 1.29 Impact Factor